Literature DB >> 19344266

Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?

Debby Ben-David1, Ilya Novikov, Leonard A Mermel.   

Abstract

OBJECTIVE: To examine the impact of methicillin resistance on in-hospital mortality, length of stay, and hospital cost after the onset of nosocomial Staphylococcus aureus bloodstream infection (BSI).
DESIGN: A retrospective cohort study.
SETTING: A tertiary care hospital in Rhode Island. PATIENTS: A cohort of 182 consecutive patients who developed nosocomial BSI due to methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively)
RESULTS: Patients with MRSA BSI had a significantly longer total length of hospital and intensive care unit (ICU) stay before the onset of BSI and a higher average daily cost. Compared with ICU patients with MSSA BSI, those with MRSA BSI had a higher median total hospital cost ($42,137 vs $113,852), higher hospital cost after infection ($17,603 vs $51,492), and greater length of stay after infection (10.5 vs 20.5 days). After multivariable adjustment, ICU patients with MRSA BSI had significantly increased total hospital cost, hospital cost after infection, and length of stay after infection. However, using a propensity score approach, we found that, among ICU patients, the difference in cost after infection and the difference in length of stay after infection for MRSA, compared with MSSA BSI, were not significant. The differences among non-ICU patients who developed MRSA or MSSA BSI were not significant after multivariable adjustment or by propensity score.
CONCLUSIONS: On the basis of propensity score, we found that methicillin resistance did not independently increase hospital cost or length of stay after onset of S. aureus BSI. We believe that use of a propensity score on a comparable subset of patients may be a better method than multivariable adjustment for assessing the impact of methicillin resistance in cohort studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344266     DOI: 10.1086/596731

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  22 in total

1.  Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit.

Authors:  Courtney A Gidengil; Charlene Gay; Susan S Huang; Richard Platt; Deborah Yokoe; Grace M Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2015-01       Impact factor: 3.254

2.  Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms.

Authors:  Matthew J Neidell; Bevin Cohen; Yoko Furuya; Jennifer Hill; Christie Y Jeon; Sherry Glied; Elaine L Larson
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

3.  Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections.

Authors:  Marlieke E A de Kraker; Martin Wolkewitz; Peter G Davey; Walter Koller; Jutta Berger; Jan Nagler; Claudine Icket; Smilja Kalenic; Jasminka Horvatic; Harald Seifert; Achim J Kaasch; Olga Paniara; Athina Argyropoulou; Maria Bompola; Edmond Smyth; Mairead Skally; Annibale Raglio; Uga Dumpis; Agita Melbarde Kelmere; Michael Borg; Deborah Xuereb; Mihaela C Ghita; Michelle Noble; Jana Kolman; Stanko Grabljevec; David Turner; Louise Lansbury; Hajo Grundmann
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

Review 4.  Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.

Authors:  Fernando Antonanzas; Carmen Lozano; Carmen Torres
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

Review 5.  Factors associated with variation in estimates of the cost of resistant infections.

Authors:  Bevin Cohen; Elaine L Larson; Patricia W Stone; Matthew Neidell; Sherry A Glied
Journal:  Med Care       Date:  2010-09       Impact factor: 2.983

6.  Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis.

Authors:  Bruce Y Lee; Rachel R Bailey; Kenneth J Smith; Robert R Muder; Elsa S Strotmeyer; G Jonathan Lewis; Paul J Ufberg; Yeohan Song; Lee H Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2010-06       Impact factor: 3.254

7.  Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.

Authors:  Assaf Raz; Anna Serrano; Maneesha Thaker; Tricia Alston; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  Statewide costs of health care-associated infections: estimates for acute care hospitals in North Carolina.

Authors:  Deverick J Anderson; Deborah G Pyatt; David J Weber; William A Rutala
Journal:  Am J Infect Control       Date:  2013-02-27       Impact factor: 2.918

9.  Implementation of a universal admission surveillance and decolonization program for methicillin-resistant staphylococcus aureus (MRSA) reduces the number of MRSA and total number of S. aureus isolates reported by the clinical laboratory.

Authors:  Donna M Hacek; Suzanne M Paule; Richard B Thomson; Ari Robicsek; Lance R Peterson
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

10.  Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study.

Authors:  Deverick J Anderson; Keith S Kaye; Luke F Chen; Kenneth E Schmader; Yong Choi; Richard Sloane; Daniel J Sexton
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.